Compare NDAQ & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NDAQ | EW |
|---|---|---|
| Founded | 1971 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.9B | 48.9B |
| IPO Year | 2001 | 1999 |
| Metric | NDAQ | EW |
|---|---|---|
| Price | $98.98 | $89.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 21 |
| Target Price | ★ $105.62 | $96.37 |
| AVG Volume (30 Days) | 2.7M | ★ 3.5M |
| Earning Date | 04-23-2026 | 04-23-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | ★ 60.10 | N/A |
| EPS | ★ 1.80 | 1.07 |
| Revenue | $4,277,000,000.00 | ★ $6,067,600,000.00 |
| Revenue This Year | $10.52 | $13.39 |
| Revenue Next Year | $8.17 | $9.81 |
| P/E Ratio | ★ $54.95 | $84.58 |
| Revenue Growth | 7.87 | ★ 11.55 |
| 52 Week Low | $76.55 | $72.30 |
| 52 Week High | $101.79 | $96.29 |
| Indicator | NDAQ | EW |
|---|---|---|
| Relative Strength Index (RSI) | 64.57 | 53.15 |
| Support Level | $96.47 | $81.19 |
| Resistance Level | $101.50 | $93.91 |
| Average True Range (ATR) | 1.75 | 1.75 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 81.07 | 42.16 |
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its trading business (about 22.5% of sales), the company sells market and financial data to investors, offers Nasdaq-branded indexes, and lists companies through its capital access segment (42.5%). Nasdaq's newest segment, financial technology, was primarily constructed through the acquisitions of Verafin and Adenza and has expanded the company into capital management, financial crime, and regulatory compliance software (35%) as it seeks to become a diversified technology company.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.